Collaborating with external peers, academia and biotechs remains central to AstraZeneca’s strategy in order for us to continue to deliver great medicines to patients through innovative science and excellent development and commercialisation.
We are one of only a handful of companies to span the entire life-cycle of a small or large medicine from discovery, early and late-stage development, to the global commercialisation of primary care, speciality care-led and speciality care medicines.
Our commitment to partnering
In March 2013 we announced the outcomes of our strategy review, designed to strengthen our ability to deliver success in the face of an increasingly tough business environment. Our overall direction stays the same but we are concentrating our skills and resources on a core set of priority pipeline projects and platforms.
Our commitment to partnering remains as strong as ever – it is a key accelerator of our strategic ambition to return to growth by strengthening the pipeline and re-establishing scientific leadership.
What do we offer?
While we seek to work with top external talent, we also bring a broad range of skills and resources to the relationship. We have leading R&D, commercial, regulatory, and market access capabilities and a global reach combined with local experience and know-how.
In addition to traditional in-licensing opportunities, our activities include;
risk sharing deals
No two deals are the same and each one is customised. We work closely with our partners to ensure both parties can leverage their unique capabilities and assets to achieve common goals. Communication is a vital part to our method of partnering and we pride ourselves on being highly responsive and engaged with our partners.
What areas are we looking to partner in?
Our strategic re-focus means we are prioritising Cardiovascular & Metabolism (CVMD), Respiratory, Inflammation & AutoImmune (RIA) and Oncology as our three core areas. While our infection and neuroscience investments will become more focused, we remain fully committed to innovative science.
Other areas include personalised healthcare and science & technology. You can find more details on these areas here.
A new approach: Biotech research units and product portfolio strategy
We are transforming our innovation model and the way we work. We have created autonomous biotech research units, comprised of the AstraZeneca Innovative Medicine and Early Development Unit (small molecule) and MedImmune (biologics).
The idea behind this is to enable us to more effectively foster innovation and accelerate decision-making across our R&D. Business development for these biotechs will be focused on sourcing early stage external opportunities that are aligned with our core therapy areas and complement our scientific capabilities.
Our new Global Product and Portfolio Strategy (GPPS), to be headed up by Marc Dunoyer, has been designed to maximise the value of our products by providing clear strategic direction from development through to commercialisation in focused therapy areas supported by business development. The guiding design principle for GPPS is that it will be a Therapy Area (TA) led organisation and BD activities will be driven by the TA priorities and will consolidate mid to late stage development and commercial opportunities across small and large molecules
In 2012 we completed over 80 deals, of which approximately one third were pre-clinical or research focused. For us, partnering is a way of life and it’s also a journey. We will continue to evolve our approach, based on feedback from our partners about what we did well and where we could do better. I look forward to having further discussion with you at the BIO Convention.